These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 10081718

  • 1. Advances in the pharmacological control of the bladder.
    Andersson KE.
    Exp Physiol; 1999 Jan; 84(1):195-213. PubMed ID: 10081718
    [Abstract] [Full Text] [Related]

  • 2. The overactive bladder: pharmacologic basis of drug treatment.
    Andersson KE.
    Urology; 1997 Dec; 50(6A Suppl):74-84; discussion 85-9. PubMed ID: 9426756
    [Abstract] [Full Text] [Related]

  • 3. Treatment of overactive bladder: other drug mechanisms.
    Andersson KE.
    Urology; 2000 May; 55(5A Suppl):51-7; discussion 59. PubMed ID: 10767453
    [Abstract] [Full Text] [Related]

  • 4. Pharmacologic perspective on the physiology of the lower urinary tract.
    Andersson KE, Hedlund P.
    Urology; 2002 Nov; 60(5 Suppl 1):13-20; discussion 20-1. PubMed ID: 12493344
    [Abstract] [Full Text] [Related]

  • 5. Treatment of the overactive bladder: possible central nervous system drug targets.
    Andersson KE.
    Urology; 2002 May; 59(5 Suppl 1):18-24. PubMed ID: 12007518
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder.
    Wein AJ.
    Expert Opin Investig Drugs; 2001 Jan; 10(1):65-83. PubMed ID: 11116281
    [Abstract] [Full Text] [Related]

  • 7. Selective beta-adrenoceptor agonists, calcium antagonists and potassium channel openers as a possible medical treatment of the overactive bladder and urge incontinence.
    Badawi JK, Langbein S.
    Pharmazie; 2006 Mar; 61(3):175-8. PubMed ID: 16599254
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recent developments in the management of detrusor overactivity.
    Kumar V, Templeman L, Chapple CR, Chess-Williams R.
    Curr Opin Urol; 2003 Jul; 13(4):285-91. PubMed ID: 12811292
    [Abstract] [Full Text] [Related]

  • 11. Potential therapeutic targets for treatment of the overactive bladder.
    Sellers DJ, Chapple CR, Chess-Williams R.
    World J Urol; 2001 Nov; 19(5):307-11. PubMed ID: 11760778
    [Abstract] [Full Text] [Related]

  • 12. CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention.
    Andersson KE, Pehrson R.
    Drugs; 2003 Nov; 63(23):2595-611. PubMed ID: 14636079
    [Abstract] [Full Text] [Related]

  • 13. Influence of central serotonergic mechanisms on lower urinary tract function.
    de Groat WC.
    Urology; 2002 May; 59(5 Suppl 1):30-6. PubMed ID: 12007520
    [Abstract] [Full Text] [Related]

  • 14. Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms.
    Andersson KE.
    Int J Clin Pract Suppl; 2006 Dec; (151):8-16. PubMed ID: 17169005
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Potential therapeutic targets for the treatment of detrusor overactivity.
    Chess-Williams R.
    Expert Opin Ther Targets; 2004 Apr; 8(2):95-106. PubMed ID: 15102552
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.